Bio Break: How to Ensure Targeted Drug Delivery Hits the Right Spot
In this episode of Bio Break, Nick Allan and Joris van der Heijden tackle the fascinating challenge of targeted drug delivery. When administering drugs to specific areas in the body, how can we be certain they reach the intended target? Nick shares an exciting example involving an intranasal device designed to deliver drugs precisely to the olfactory cleft—an area located between the eyes.
From initial bench modeling with plastic nose prototypes to sophisticated human trials, the episode breaks down the multi-step process used to confirm drug deposition. Learn how techniques like using food coloring on prototypes and delivering radiotracer technetium-99 for imaging helped refine their approach. Nick dives into the advanced use of CT scans and radioactivity mapping, followed by real-world testing with medical-grade methylene blue and ENT scope visualization.
The team showcases how the integration of engineering, human trials, and medical-grade testing leads to reliable results in targeted delivery systems. Discover why these detailed studies are crucial for verifying that drugs reach their destination, ensuring safety and effectiveness.
Whether you’re a medical professional, device developer, or simply intrigued by how cutting-edge drug delivery works, this episode offers insights into the science and technology behind targeted solutions.
Key Topics Covered:
- Real-world examples of ensuring precision drug delivery
- Targeted drug delivery to the olfactory cleft
- Using radiotracers like technetium-99 in imaging trials
- Employing methylene blue for visible deposition tracking
- Challenges and solutions in intranasal device testing
How to Ensure Targeted Drug Delivery Hits the Right Spot
Related Resources
Connected health devices are multiplying fast. We examine the gap between remote monitoring’s promise and its reality.
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.